Document Detail


Early administration of vapreotide for variceal bleeding in patients with cirrhosis.
MedLine Citation:
PMID:  11136956     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: In patients with cirrhosis, pharmacologic or endoscopic treatment may control variceal bleeding. However, the effects of early administration of a somatostatin analogue followed by endoscopic treatment are unknown. METHODS: We studied the effects of treatment with vapreotide, a somatostatin analogue, begun before endoscopic treatment in 227 patients with cirrhosis who were hospitalized for acute upper gastrointestinal bleeding. The patients were randomly assigned to receive vapreotide (a 50-microg intravenous bolus followed by an infusion at a rate of 50 microg per hour for five days) or placebo within a mean (+/-SD) of 2.3+/-1.5 hours after admission. All the patients received endoscopic treatment a mean of 2.6+/-3.3 hours after the infusion was begun. After the exclusion of 31 patients whose bleeding was not caused by portal hypertension, there were 98 patients in each group. RESULTS: At the time of endoscopy, active bleeding was evident in 28 of 91 patients in the vapreotide group (31 percent), as compared with 43 of 93 patients in the placebo group (46 percent) (P=0.03). During the five-day infusion, the primary objective--survival and control of bleeding--was achieved in 65 of 98 patients in the vapreotide group (66 percent) as compared with 49 of 98 patients in the placebo group (50 percent) (P=0.02). The patients in the vapreotide group received significantly fewer blood transfusions (2.0+/-2.2 vs. 2.8+/-2.8 units, P=0.04). Overall mortality rates at 42 days were not significantly different in the two groups. CONCLUSIONS: In patients with cirrhosis and variceal bleeding, the combination of vapreotide and endoscopic treatment is more effective than endoscopic treatment alone as a method of controlling acute bleeding. However, the use of combination therapy does not affect mortality rates at 42 days.
Authors:
P Calès; C Masliah; B Bernard; P P Garnier; C Silvain; N Szostak-Talbodec; J P Bronowicki; D Ribard; D Botta-Fridlund; P Hillon; K Besseghir; D Lebrec;
Related Documents :
525316 - Synoviorthesis with radioactive gold in hemophiliacs. clinical and radiological follow-up.
2832586 - Ectopic gastric mucosa in rectum: a rare cause of rectal bleeding in children.
20735906 - The effect of local compression and topical epinephrine on perioperative bleeding and d...
20054306 - Editorial: upper gi bleeding-associated mortality: challenges to improving a resistant ...
22554426 - The role of open and endovascular treatment with fenestrated and chimney endografts for...
20627786 - Treatment interruptions among patients with tuberculosis in russian tb hospitals.
Publication Detail:
Type:  Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  The New England journal of medicine     Volume:  344     ISSN:  0028-4793     ISO Abbreviation:  N. Engl. J. Med.     Publication Date:  2001 Jan 
Date Detail:
Created Date:  2000-12-20     Completed Date:  2001-01-04     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0255562     Medline TA:  N Engl J Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  23-8     Citation Subset:  AIM; IM    
Affiliation:
Services d'Hépato-Gastoentérologie, Centres Hospitaliers of Angers, France. paul.cales@med.univ-angers.fr
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Blood Transfusion
Combined Modality Therapy
Endoscopy
Esophageal and Gastric Varices / drug therapy*,  etiology,  mortality,  therapy
Female
Gastrointestinal Hemorrhage / drug therapy*,  etiology,  mortality,  therapy
Humans
Hypertension, Portal / complications
Liver Cirrhosis / complications*,  mortality
Male
Middle Aged
Multivariate Analysis
Recurrence / prevention & control
Sclerotherapy
Somatostatin / analogs & derivatives*,  therapeutic use*
Chemical
Reg. No./Substance:
0/vapreotide; 51110-01-1/Somatostatin
Comments/Corrections
Comment In:
J Hepatol. 2002 Jul;37(1):167-8   [PMID:  12076882 ]
Z Gastroenterol. 2003 Jan;41(1):151-3   [PMID:  16308925 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The pathogenesis of acute pulmonary edema associated with hypertension.
Next Document:  Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription.